Haleon (HLNCF) Equity Ratio (2021 - 2025)

Haleon (HLNCF) recorded quarterly Equity Ratio of 0.5 in Q4 2025, up 6.47% on a QoQ basis from 0.47 in Q4 2024, and up 6.47% year-over-year from 0.47 in Q4 2024.

Haleon (HLNCF) Equity Ratio (2021 - 2025) Analysis & Trends

Haleon has disclosed Equity Ratio across 5 years of filings, most recently posting 0.5 for Q4 2025.

  • Quarterly Equity Ratio rose 6.47% year-over-year to 0.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.5 (up 6.47% YoY) and the FY2025 annual result came in at 0.5, up 6.47% from the prior year.
  • Equity Ratio climbed to 0.5 in Q4 2025, from 0.47 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.77 in Q4 2021 and troughed at 0.47 in Q4 2022.
  • A 5-year average of 0.54 and a median of 0.49 in 2023 frame the typical range for Equity Ratio.
  • Annual changes were most pronounced in 2022 — Equity Ratio sank 38.5% — and 2025, when it grew 6.47%.
  • Tracing HLNCF's Equity Ratio over 5 years: stood at 0.77 in 2021, then slumped by 38.5% to 0.47 in 2022, then increased by 3.92% to 0.49 in 2023, then decreased by 3.75% to 0.47 in 2024, then climbed by 6.47% to 0.5 in 2025.
  • Business Quant data shows HLNCF's Equity Ratio at 0.5 in Q4 2025, 0.47 in Q4 2024, and 0.49 in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 0.21
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 0.21
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 0.88
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 0.73
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 0.69
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 0.49
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 0.41
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 0.20
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 0.52
10 Haleon - - - 0.50

Historic Data

Download Data
DateValue
Dec 31, 2025 0.50
Dec 31, 2024 0.47
Dec 31, 2023 0.49
Dec 31, 2022 0.47
Dec 31, 2021 0.77